FDA clears NeuWave's soft tissue ablation system
NeuWave Medical, a spin-off company from the University of Wisconsin, Madison, has been granted FDA marketing clearance for its Certus 140TM 2.45 GHz ablation system to be used in the coagulation of soft tissue.
The system—which can be utilized for both minimally invasive percutaneous procedures and open surgery—operates by employing microwave energy to ablate soft tissue and help decrease bleeding and other complications, the company said.
The system—which can be utilized for both minimally invasive percutaneous procedures and open surgery—operates by employing microwave energy to ablate soft tissue and help decrease bleeding and other complications, the company said.